The Hematology/Oncology Division provides care to children with blood and cancer disorders at CHEO.

The objective of the Division is to provide high quality, comprehensive, multidisciplinary care, education and research opportunities, and to advocate on behalf of children and youth with blood disorders and cancers.

The Division’s faculty consists of seven full-time and two part-time members who are dedicated to optimizing care and training for the pediatricians and hematologists/pediatric oncologists of tomorrow. We share an interest in the ongoing professional development of our physicians and in maintaining high education levels.

The Division participates in numerous clinical trials, including those led by the Children’s Oncology Group (International), the C17 Research Network (Canada), the Canadian Cancer Society and the National Cancer Institute of Canada.
The Division is a member of the Pediatric Oncology Group of Ontario (POGO), the C17 Children’s Cancer and Blood Disorders Network and the Children’s Oncology Group, among others.

Clinical programs

Hospital care

The Hematology/Oncology Division provides both inpatient and consultation services. Patients are admitted to CHEO to the 4North unit under the care of their hematologist/oncologist.

Outpatient care

Outpatient care is provided in the clinic in the Gary Cardiff wing. Clinics are conducted on a daily basis for various subspecialties, including:

  • oncology
  • oncology follow-up (children and adults)
  • ortho-oncology
  • bone marrow transplant
  • neuro-oncology
  • hemoglobinopathies (sickle cell disease, thalassemia)
  • benign hematologic conditions
  • hemophilia/Von Willebrand disease
  • hematology/gynecology for adolescents
  • thrombosis
  • home and school consultations (Interlink paediatric community nurse)
  • individual and group education session
  • evaluation and monitoring of clinical problems and diseases

Laboratory and diagnostic programs

The hematology laboratory at CHEO performs basic hematology tests as well as special tests. Flow cytometry is performed at The Ottawa Hospital. CHEO also has a cytogenetic laboratory. The newborn screening laboratory for the region is also located at CHEO.

Laboratory analyses performed by members of the Division include:

  • lumbar puncture
  • lumbar puncture and intrathecal chemotherapy
  • bone marrow aspiration
  • bone marrow biopsy


The Hematology/Oncology Division is actively involved in clinical and academic research, as well as research on health care delivery. All members of our team are part of the Children’s Oncology Group (International). We are currently conducting over 50 therapeutic and biological studies at CHEO.

The Division contributes to research in the following areas:

Clinical research

  • Children’s Oncology Group: 12 treatment studies, 10 biology studies and 5 support care studies are underway at CHEO
  • A study of metronome administration of topotecal and pazopanib in children with recurrent or refractory solid tumours.
  • Evaluation of the efficacy and safety of rivipansel in the treatment of vaso-occlusive crisis in children with sickle cell disease.
  • Mutations in dysplasias, dysontogenetic disease, tumours and other diseases.
  • Improving the quality of life of children with cancer through psychosocial screening and better communication.
  • Initiative to maximize progress in adolescent cancer treatment.
  • Adrenal insufficiency in children with acute lymphoblastic leukemia during treatment.
  • Assessment of respiratory difficulties in adult childhood cancer survivors.
  • Exploring the feasibility, safety and potential benefits of a 12-week in-home physical activity program for children with cancer.
  • Immunization of children after chemotherapy to treat acute lymphoblastic leukemia: A study by the Canadian Immunization Research Network.
  • Very long-term neurocognitive and endocrine outcomes in childhood cancer survivors.
  • Perspectives on experimental fertility preservation techniques.
  • Validation of a self-assessment questionnaire on bleeding in children.
  • Central venous catheter dysfunction as a predictive factor for thromboembolism in children with cancer.
  • Exploring perceptions of social support for physical activity among cancer survivors and their parents.
  • Treatment of venous thrombosis by oral administration of rivaroxaban.
  • Biomarkers for the long-term effects of cancer treatment in children.
  • Anticoagulant treatment with dabigatran.
  • Osteonecrosis in children with acute lymphoblastic leukemia.
  • Study to determine the dose of melatonin for children with recurrent solid tumours.
  • Hereditary spinal cord aplasia syndromes
  • Quality of life assessment for individuals with idiopathic thrombopenic purpura.
  • Assessing quality of life in children and adults with thalassemia major.
  • Assessment of quality of life specific to myelodysplasia.
  • Blood borne pathogens surveillance project.
  • Comparison of IVIG alone and IVIG with steroids for the treatment of idiopathic thrombopenic purpura.
  • Predicting, diagnosing and treating late cardiac effects in childhood cancer survivors.
  • Canadian database on hemophilia (CHARMS)
  • National sickle cell registry

Healthcare delivery research

  • Effect of virtual consultations in paediatric specialty.
  • Effect of neonatal screening on hemoglobinopathy and complications with the disease in children in Ontario.
  • Effects of Syrian refugees on health services in Canada.
  • Physician decisions for the treatment of idiopathic thrombopenic purpura and patient-reported results.
  • Assessing and supporting physical literacy in Ontario children with medical conditions and disabilities.
  • Effect of idiopathic thrombopenic purpura diagnostic pathway on children’s initial health-related quality of life.
  • Registration of adolescents and young adults with cancer in clinical trials.
  • Development of a validated algorithm to identify immigrant children with hemoglobinopathy in Ontario.
  • Electronic pain diary for youth with cancer.
  • Transition to meaningful activity for childhood cancer survivors.
  • Development and evaluation of an online program for independent management and transitional care for youth with cancer.

University research

  • Assessment of resident experience in the learning environment.

Training programs

Undergraduate training program

The Division provides comprehensive education in a variety of forms to undergraduate trainees:

  • Optional internships (2-3 weeks in hospital).
  • Optional observation courses (10 to 12 hours in an outpatient setting).
  • Elective placements (two weeks in an outpatient setting).

Postdoctoral education

Specialty residency in hematology/oncology (fellowship)

The Hematology/Oncology Division supports and oversees an accredited subspecialty residency program that is highly effective and valued. It is a three-year program at the Royal College of Physicians and Surgeons of Canada. Many people have graduated from this program.

Full details of the post-doctoral program are available at the following link: hematology/oncology fellowship.

Additional postdoctoral education

Some residency programs include a mandatory four-week placement in pediatric hematology/oncology. This internship provides valuable experience in inpatient and outpatient settings. These settings include general pediatrics, palliative care medicine, adult hematology, pediatric gynecology and adult hematopathology